AzTrials
AzTrials

Autism Spectrum DisorderCAT-Q/DENCT05989685

Psychometric Validation of the Camouflaging Autistic Traits Questionnaire

An observational study of Autism Spectrum Disorder, run by Universitätsklinikum Hamburg-Eppendorf at 1 site in Germany.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

For many affected individuals, despite impairment and distress, autism spectrum disorder (ASD) is recognized and diagnosed late, in school age, adolescence, or even in adulthood, which could be due, among other things, to the use of compensatory strategies such as so-called "camouflaging" by the respective individual. Read more about this study

Who is it for?
Ages 13 to 21 years
Conditions the study is for
Autism Spectrum Disorder
How many people
622 participants
Where
1 siteGermany
Study dates
20 Feb 2023to Sep 2025
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 13 to 21 years
  • All sexes
  • Child, Adult

Study population: Patients treated at the Department of Child and Adolescent Psychiatry, Psychotherapy, and Psychosomatics at the UKE and the joint practice - KJP Praxis Hoheluft, as well as other participants who meet the diagnostic criteria of an autism spectrum disorder will be included in the study. Interrater reliability between the sites will be recorded and assessed to ensure that the diagnostic criteria of an autism spectrum disorder are applied consistently between the two sites. The control group will be recruited through Bilendi-Respondi, a market research service provider.

Who may be able to join

  • patients who meet the principal diagnosis of ASD, which includes atypical autism (ICD-10: F84.1) and Asperger syndrome (ICD-10: F84.5), and are between the ages of 13 and 21 years old.
  • Adolescents who do not have a lifetime principal diagnosis of a psychiatric disorder (ICD-10-GM-2016: F10 - F69) and are between 13 and 21 years old.

Who cannot join

  • Dementia / below average cognitive abilities (IQ < 85)
  • lack of German language skills
  • severe visual or hearing impairment (uncorrected)
  • dementia / below average general cognitive ability (IQ < 85)
  • lack of German language skills
  • severe impairment of vision or hearing (not corrected).

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Johannes Boettcher, Dr. contact

040 7410-52202 ext. +49

j.boettcher@uke.de

Germany1 site, 1 recruiting
  • University Medical Center Hamburg-Eppendorf

    Hamburg, 20251

    Johannes Boettcher, Dr.

    Recruiting

Other trials in Germany

About this study

Official title: Psychometric Validation of the Camouflaging Autistic Traits Questionnaire (CAT-Q/DE) in a German Population of Autistic and Non-autistic Adolescents.

For many affected individuals, despite impairment and distress, autism spectrum disorder (ASD) is recognized and diagnosed late, in school age, adolescence, or even in adulthood, which could be due, among other things, to the use of compensatory strategies such as so-called "camouflaging" by the respective individual. In order to better investigate and quantify these adaptive and compensatory strategies of individuals with autism, the Camouflaging Autistic Traits Questionnaire (CAT-Q) has recently been developed and validated in the English-speaking world. The CAT-Q is designed to assess the extent of camouflaging behavior, in which autistic individuals consciously or unconsciously attempt to conceal or attenuate their autistic traits in order to better adapt to social situations. So far, however, there is no German-language questionnaire that can be used to validly assess camouflaging. The aim of the planned research project is to psychometrically validate the CAT-Q in German-speaking adolescents aged 13-21 years. The validation of the CAT-Q represents an important basis for further research on the construct camouflaging and can subsequently contribute to an improvement of diagnostics as well as support the development of individual treatment approaches.

Keywords
Camouflaging, Late diagnosis, Adolescents
Medical subject headings
Autism Spectrum Disorder

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT05989685
Study groupRoleWhat they receive
Study groupAdolescents between the ages of 13-21 who meet diagnostic criteria for an autism spectrum disorder.
Control groupAdolescents aged 13-21 years without a lifetime psychiatric diagnosis.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Camouflaging

    Camouflaging Autistic Traits Questionnaire (CAT-Q; Hull et al., 2019) is a quantitative measure of camouflaging. The CAT-Q can be used as a self-report and parent report version. The CAT-Q was constructed to be appropriate for both autistic and non-autistic populations (Hull et al., 2019). The instrument includes 25 items that are answered on a seven-point Likert scale.

    Measured: 3-4 minutes

Secondary outcomes (10)
  1. Autistic Traits

    The Social Responsiveness Scale (SRS-16; Constantino et al., 2003) is a quantitative measure of autistic traits in children, adolescents, and adults. The SRS-16 (Sturm et al., 2017) is a 16-item parent questionnaire assessing social, communicative, and rigid behaviors in children and adolescents in terms of a dimensional diagnosis of autism.

    Measured: 3 minutes

  2. Mental health

    The Strengths and Difficulties Questionnaire (SDQ; Goodman, 1997) is one of the most frequently used methods for assessing mental health in children and adolescents from a self- and parent perspective. In addition to the version for children and adolescents, there is also a version for adults, the SDQ 18+. The SDQ assesses mental health problems and resources of children and adolescents with 5 items each on five subscales: behavioral problems, emotional problems, hyperactivity, peer problems, and prosocial behavior. It has good psychometric properties, is economical, and has been widely used in research (Goodman, 2001).

    Measured: 4 minutes

  3. Symptoms of depression

    The Patient Health Questionnaire scale 9 (PHQ-9; (Kroenke et al., 2001), is a self-report questionnaire designed to assess the severity of depressive disorder in adolescents and adults. The PHQ-9 has been shown to display good psychometric properties and has been validated in autistic adolescents and adults (Arnold et al., 2020).

    Measured: 1 minutes

  4. Symptoms of anxiety

    The Generalized Anxiety Disorder scale 7 (GAD-7; Spitzer et al., 2006), is a self-report questionnaire designed to assess the severity of anxiety in adolescents and adults. The GAD-7 has been validated in adolescent and adult populations, displaying good psychometric properties (Löwe et al., 2008). The GAD-7 is strongly correlated with anxiety measures including the Beck Anxiety Inventory (Spitzer et al., 2006) and provides a valid measure also of other anxiety disorders, e.g. social anxiety and panic disorder (Kroenke et al., 2007).

    Measured: 1 minutes

  5. Stress

    The Perceived Stress Scale (PSS-10; Schneider et al., 2020) is a 10-item questionnaire commonly used to assess stress levels in adolescents and adults 12 years and older. It assesses the extent to which a person has perceived life as unpredictable, uncontrollable, and overwhelming in the past month.

    Measured: 1 minutes

  6. Loneliness

    3-item Loneliness Scale (Klein et al., 2021): Loneliness is also measured by the 3-item Loneliness Scale. The scale is an economic measure derived from the R-UCLA Loneliness Scale (Russell et al., 1980) that captures basic aspects of loneliness: A sense of isolation, disconnectedness, and not belonging. Items are rated on 5-point Likert scales. Responses are summed for a total score ranging from 0 to 12, with higher scores indicating higher levels of loneliness. Autism related adaptations of the instrument was made according to recent research (Grace et al., 2023).

    Measured: 1 minute

  7. Mentalizing

    The Reflective Function Questionnaire for Youth-5 (RFQ-Y; Sharp et al., 2022) measures mentalizing ability in adolescents. The English version showed satisfactory psychometric properties (Sharp et al., 2022).

    Measured: 1 minute

  8. Theory of Mind

    The Frith-Happé Animations Test (Livingston et al., 2021), which represents interactions between triangles in animations, is an online instrument for measuring Theory of Mind (ToM). The web-based version of this test provides a quick and objective measurement of the construct ToM using multiple-choice questions. The instrument demonstrated good psychometric properties in a clinical as well as a non-clinical sample (Livingston et al., 2021).

    Measured: 3-4 minutes

  9. Emotion Regulation

    The Difficulties in Emotion Regulation Scale (DERS; Gratz and Roemer, 2004) was used to measure difficulties in emotion regulation. Although there are different versions, this study we will use the short version with 8 items as suggested by Penner \& Sharp, 2022. The DERS-8 has shown good psychometric properties (Penner \& Sharp, 2022).

    Measured: 1 minute

  10. Parent-Adolescent Communication

    The quality of dyadic Parent-Adolescent Communication was assessed with the German translation of the Parent-Adolescent Communication Scale (PACS; Barnes \& Olson, 1982). The original measure consists of an adolescent and a parent version with 20 identical items that are rated on a scale from 1 ("strongly disagree") to 5 ("strongly agree"). The German version of the instrument has shown acceptable psychometric properties (Zapf \& Boettcher, 2024)

    Measured: 2-3 minutes

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Aug 2023
  2. Study start20 Feb 2023
  3. Primary completionAug 2025 (estimated)
  4. Study completionSep 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Cross-sectional
Enrolment
622 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05989685
Sponsor's protocol ID
LPEK-0659
Acronym
CAT-Q/DE
Status last verified
Mar 2025
First submitted
4 Aug 2023
Last updated
12 Mar 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Boettcher J, Zapf H, Daubmann A, Schimmelmann B, Bindt C, Hohmann S, Micheel J. Assessing Camouflaging in Adolescence: Psychometric Evaluation of the German Camouflaging Autistic Traits Questionnaire (CAT-Q/DE). J Autism Dev Disord. 2026 Jul 2. doi: 10.1007/s10803-026-07423-z. Online ahead of print.

    PubMed 42387100

Questions about this trial

What is this clinical trial studying?

An observational study of Autism Spectrum Disorder, run by Universitätsklinikum Hamburg-Eppendorf at 1 site in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 12 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Johannes Boettcher, Dr. (040 7410-52202 ext. +49, j.boettcher@uke.de), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Camouflaging (time frame: 3-4 minutes). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05989685, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Mar 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in